Garrett Heinrich Selected Research

CEACAM1 Protein

1/2018	Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis.
12/2017	Liver-specific reconstitution of CEACAM1 reverses the metabolic abnormalities caused by its global deletion in male mice.
1/2017	Loss of Hepatic CEACAM1: A Unifying Mechanism Linking Insulin Resistance to Obesity and Non-Alcoholic Fatty Liver Disease.
1/2017	Reduced Hepatic Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Level in Obesity.
12/2016	Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis.
5/2016	Leptin Resistance Contributes to Obesity in Mice with Null Mutation of Carcinoembryonic Antigen-related Cell Adhesion Molecule 1.
4/2016	PPARα (Peroxisome Proliferator-activated Receptor α) Activation Reduces Hepatic CEACAM1 Protein Expression to Regulate Fatty Acid Oxidation during Fasting-refeeding Transition.
8/2015	Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance.
1/2015	Hepatic CEACAM1 Over-Expression Protects Against Diet-Induced Fibrosis and Inflammation in White Adipose Tissue.
8/2013	Ceacam1 deletion causes vascular alterations in large vessels.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Garrett Heinrich Research Topics

Disease

14	Insulin Resistance 01/2018 - 09/2008
8	Hyperinsulinism (Hyperinsulinemia) 01/2018 - 09/2008
6	Fatty Liver 01/2018 - 08/2013
6	Obesity 12/2017 - 05/2016
4	Hyperphagia (Overeating) 12/2017 - 08/2010
4	Abdominal Obesity 01/2017 - 01/2015
2	Hepatocellular Carcinoma (Hepatoma) 01/2018 - 04/2016
2	Body Weight (Weight, Body) 01/2018 - 10/2013
2	Non-alcoholic Fatty Liver Disease 01/2017 - 12/2008
2	Fibrosis (Cirrhosis) 01/2015 - 12/2008
1	Metabolic Diseases (Metabolic Disease) 01/2017
1	Type 2 Diabetes Mellitus (MODY) 11/2016
1	Dyslipidemias (Dyslipidemia) 11/2016
1	Inflammation (Inflammations) 01/2015
1	Weight Gain 11/2011
1	Glucocorticoid Receptor Deficiency 09/2010
1	Hepatitis 12/2008
1	Hypertrophy 05/2008
1	Cardiovascular Diseases (Cardiovascular Disease) 05/2008
1	Mycoses (Diseases, Fungus) 01/2003

Drug/Important Bio-Agent (IBA)

12	CEACAM1 ProteinIBA 01/2018 - 09/2008
12	Insulin (Novolin)FDA Link 01/2018 - 09/2008
5	LipidsIBA 12/2017 - 01/2015
3	Fatty Acid Synthases (Fatty Acid Synthase)IBA 12/2017 - 08/2010
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2018 - 04/2016
2	Cell Adhesion MoleculesIBA 09/2017 - 01/2016
2	CD66 antigensIBA 09/2017 - 01/2016
2	Glucose (Dextrose)FDA LinkGeneric 09/2017 - 04/2016
2	Carcinoembryonic AntigenIBA 09/2017 - 01/2016
1	Retinoid X Receptor alphaIBA 01/2018
1	Exenatide (Byetta)FDA Link 01/2018
1	Fenofibrate (CiL)FDA LinkGeneric 11/2016
1	Pharmaceutical PreparationsIBA 11/2016
1	Fatty Acids (Saturated Fatty Acids)IBA 11/2016
1	LeptinIBA 05/2016
1	Messenger RNA (mRNA)IBA 04/2016
1	pirinixic acidIBA 04/2016
1	Triglycerides (Triacylglycerol)IBA 08/2015
1	Anti-Obesity Agents (Antiobesity Drugs)IBA 10/2013
1	Insulin ReceptorIBA 11/2011
1	CytokinesIBA 11/2011
1	glucocorticoid receptor betaIBA 09/2010
1	Protein Isoforms (Isoforms)IBA 09/2010
1	NF-kappa B (NF-kB)IBA 12/2008
1	Proteins (Proteins, Gene)FDA Link 12/2008
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2008
1	ProcollagenIBA 12/2008
1	Carbon MonoxideIBA 05/2008
1	SmokeIBA 05/2008
1	EnzymesIBA 01/2003

Therapy/Procedure

1	Intraperitoneal Injections 01/2018